Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

35 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-31

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who were initially treated with Cyclosporine Ophthalmic Emulsion 0.05% but discontinued use after less than 12 weeks of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

NCT02121847

Dry Eye Syndromes

COMPLETED PHASE4

Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers

NCT00335114

Contact Lens Wearers With Dry Eye Syndrome

COMPLETED NA

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

NCT00717418

Keratoconjunctivitis Sicca

COMPLETED

Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis

NCT00884585

Atopic Conjunctivitis

COMPLETED PHASE3

Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms

NCT00399061

Dry Eye

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients who received Restasis®

Patients who received Restasis® (cyclosporine ophthalmic emulsion 0.05%)

Cyclosporine Ophthalmic Emulsion 0.05%

Intervention Type DRUG

One drop two times a day approximately 12 hours apart

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cyclosporine Ophthalmic Emulsion 0.05%

One drop two times a day approximately 12 hours apart

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RESTASIS®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults \>16 years of age
* Dry eye patients
* Subject with history of less than 12 weeks of initial RESTASIS® treatment
* Subject started second trial of RESTASIS® treatment prior to June 1, 2008
* First day of second trial of RESTASIS® started ≥ 4 weeks after the last day of previous RESTASIS® treatment